Page last updated: 2024-11-04

sb 202190 and Dermatitis

sb 202190 has been researched along with Dermatitis in 5 studies

4-(4-fluorophenyl)-2-(4-hydroxyphenyl)-5-(4-pyridyl)imidazole: structure given in first source; inhibits p38 MAP kinase

Dermatitis: Any inflammation of the skin.

Research

5 other studies available for sb 202190 and Dermatitis

Article	Year
Role of p38 mitogen-activated protein kinase isoforms in murine skin inflammation induced by 12-O-tetradecanoylphorbol 13-acetate. Acta dermato-venereologica, 2011, Volume: 91, Issue:3 Topics: Animals; Dermatitis; Disease Models, Animal; Enzyme Activation; Enzyme-Linked Immunosorbent Assay; F	2011
p38 Mitogen-activated protein kinase inhibitor protects the epidermis against the acute damaging effects of ultraviolet irradiation by blocking apoptosis and inflammatory responses. The Journal of investigative dermatology, 2004, Volume: 122, Issue:2 Topics: Acute Disease; Animals; Apoptosis; Dermatitis; Enzyme Inhibitors; Epidermis; Imidazoles; Male; MAP K	2004
CCL28 production in HaCaT cells was mediated by different signal pathways from CCL27. Experimental dermatology, 2006, Volume: 15, Issue:2 Topics: Cell Line; Chemokine CCL27; Chemokines; Chemokines, CC; Dermatitis; Humans; Imidazoles; Interleukin-	2006
Topical p38MAPK inhibition reduces dermal inflammation and epithelial apoptosis in burn wounds. Shock (Augusta, Ga.), 2006, Volume: 26, Issue:2 Topics: Administration, Topical; Animals; Apoptosis; Burns; Chemokines, CXC; Cytokines; Dermatitis; Dose-Res	2006
Topical p38 MAPK inhibition reduces bacterial growth in an in vivo burn wound model. Surgery, 2007, Volume: 142, Issue:1 Topics: Administration, Topical; Animals; Burns; Chemokine CXCL2; Chemokines, CXC; Colony-Forming Units Assa	2007